0.10 SEK
(1.85%)
Add to watchlist
Create an alert
Stocks and Shares ISACantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Company Information
About this company
Key people
Hilde H. Steineger
Chief Executive Officer
Patrik Renblad
Chief Financial Officer
Susanne Lagerlund
Vice President - Regulatory Affairs
David Liberg
Vice President - Research
Nedjad Losic
Vice President - Biometrics
Peter Jull Madsen
Vice President - CMC
Lars Thorsson
Vice President - Clinical Development
Ton Berkien
Chief Business Officer
Wolfram Dempke
Chief Medical Officer
Magnus Modee Persson
Independent Chairman of the Board
Damian Marron
Non-Executive Director
Flavia Borellini
Independent Director
Anders Martin-Loef
Independent Director
Carl Magnus Walter Nilsson
Independent Director
Click to see more
Key facts
- Shares in issue248.61m
- EPICCANTA
- ISINSE0006371126
- LocationSweden
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capSEK 1.34bn
- Employees23
- ExchangeStockholm Stock Exchange
- IndexSX All Share PI Market Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.